Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipocine, a specialty pharmaceutical company, has successfully completed a clinical study that establishes feasibility of the first once-a-day dosing product for Ziprasidone, a leading treatment for schizophrenia and bipolar disorder.
Subscribe to our email newsletter
The company plans to call for co-development of this product with a marketing partner.
Mahesh Patel, president and CEO of Lipocine, said: “Our patented Lip’ral-SSR technology enabled this breakthrough for the ‘once-a-day’ formulation that will improve patient compliance in a meaningful way for schizophrenia and bipolar disorder sufferers.
“In addition, sustained release formulations enabled by Lipocine’s Lip’ral SSR technology offer the potential to improve therapy and side effect profile for drugs such as Ziprasidone.”